The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Theratechnologies will need to address FDA's concerns about whether a reduction of patients' visceral abdominal fat produced by the HIV lipodystrophy product has clinical meaning and is worth the risks.
You may also be interested in...
Egrifta Post-marketing Study On Diabetic Retinopathy Will Include CV Outcomes
FDA’s decision to require a post-approval clinical trial evaluating the cardiovascular effects of Theratechnologies’ HIV lipodystrophy drug Egrifta shows the agency has overcome concerns – both its own and those of its advisory committee – that such a study could not be feasibly and ethically conducted.
Egrifta Post-marketing Study On Diabetic Retinopathy Will Include CV Outcomes
FDA’s decision to require a post-approval clinical trial evaluating the cardiovascular effects of Theratechnologies’ HIV lipodystrophy drug Egrifta shows the agency has overcome concerns – both its own and those of its advisory committee – that such a study could not be feasibly and ethically conducted.
Delayed Egrifta Approval Brings Clean Label, No REMS For Theratechnologies
Tesamorelin becomes the first drug approved by FDA to treat HIV-related lipodystrophy.